network member

University of Illinois Cancer Center

914 S. Wood Street, Chicago, IL 60612
University of Illinois Cancer Center

About Network Member

The University of Illinois Cancer Center is a science-first research institution that gives every patient with cancer equal access to world-class treatment. More than 230 Cancer Center physicians and scientists are dedicated to equitable cancer care and no patient is ever turned away. The Cancer Center is focused on creating equity by providing optimal cancer treatment to patients who are historically under-represented in research and clinical trials. The diversity of our patients improves scientific understanding of how biology and societal factors contribute to an unequal cancer burden. Researchers are unlocking the mysteries of cancer by integrating genetics, basic science and public health information to identify factors that influence the frequency and severity of disease. Using state-of-the-art cancer biomarkers, the Cancer Center optimizes treatment for every patient’s individual disease. We work in the communities we serve to prevent cancer, discover effective new treatments for patients and uncover new information about the disease. Patients from diverse communities are involved in every aspect of our work, informing our research and helping remove barriers to effective treatment. We connect people with the resources they need to understand their cancer risk, detect it early and get comprehensive treatment. Our patients can receive promising cancer therapies before they are widely available, closing the gap between underrepresented communities and access to better treatments. The University of Illinois Cancer Center provides clinical care through UI Health, an academic medical center that comprises a 462-bed tertiary care hospital, 21 outpatient clinics, and 14 Federally Qualified Health Centers (FQHCs). Member research is conducted in partnership with the seven University of Illinois Chicago (UIC) health science colleges: the College of Applied Health Sciences; the College of Dentistry; the School of Public Health, the Jane Addams College of Social Work; and the Colleges of Medicine, Pharmacy and Nursing.
Currently Enrolling

HCRN-BRE17-141

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers
Cancer areas:Breast
Penn State Cancer Institute
University of Illinois Cancer Center
University of Rochester Medical Center - Wilmot Cancer Institute
University of Wisconsin Carbone Cancer Center
Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
New York University Cancer Institute
Orlando Health Cancer Institute
Parkview Research Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
Tufts Medical Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Arizona Cancer Center
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Michigan Health-West
University of Michigan Rogel Cancer Center
University of Virginia Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-BRE15-024

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024
Cancer areas:Breast
University of Illinois Cancer Center
University of Rochester Medical Center - Wilmot Cancer Institute
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111
Cancer areas:Head and Neck
Masonic Cancer Center, University of Minnesota
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
University of Michigan Rogel Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Virginia Commonwealth University
Currently Enrolling

BTCRC-LUN20-462

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second Line Treatment for Small Cell Lung Cancer
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Currently Enrolling

BTCRC-LYM20-463

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Cancer areas:Lymphoma
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Rutgers Cancer Institute of New Jersey
The Ohio State University
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

HCRN-GU16-260

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma
Cancer areas:Kidney
Beth Israel Deaconess Medical Center
Cleveland Clinic Cancer Center
Columbia University Irving Medical Center
Fox Chase Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Penn Medicine Abramson Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Winship Cancer Institute of Emory University
Yale Cancer Center
Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Cancer areas:Lung
Barbara Ann Karmanos Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Summit Health Cancer Center
University of Illinois Cancer Center
University of Virginia Cancer Center
Enrollment Closed

BTCRC-AML17-113

Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
Cancer areas:Leukemia
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of Illinois Cancer Center
Enrollment Closed

BTCRC-BRE18-337

Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337
Cancer areas:Breast
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-BRE19-409

A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination with Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE19-409
Cancer areas:Breast
Fred & Pamela Buffett Cancer Center
Penn State Cancer Institute
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-GI20-457

A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma (The AB7 Trial) Big Ten Cancer Research Consortium BTCRC-GI20-457
Cancer areas:Liver and Bile Duct
DHR Health
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
New York University Cancer Institute
Rutgers Cancer Institute of New Jersey
University of Illinois Cancer Center
University of Wisconsin Carbone Cancer Center
Enrollment Closed

BTCRC-LUN18-363

A Phase II Study of Chemo-Immunotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Big Ten Cancer Research Consortium BTCRC-LUN18-363
Cancer areas:Lung
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Ohio State University
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center